Quantification of HER family receptors in breast cancer

Paolo Nuciforo; Nina Radosevic-Robin; Tony Ng; Maurizio Scaltriti

doi:10.1186/s13058-015-0561-8

Quantification of HER family receptors in breast cancer

Paolo Nuciforo, Nina Radosevic-Robin, Tony Ng, Maurizio Scaltriti^*

^*Corresponding author for this work

Cell Imaging

Research output: Contribution to journal › Article › peer-review

43 Citations (Scopus)

254 Downloads (Pure)

Abstract

The clinical success of trastuzumab in breast cancer taught us that appropriate tumor evaluation is mandatory for the correct identification of patients eligible for targeted therapies. Although HER2 protein expression by immunohistochemistry (IHC) and gene amplification by fluorescence in situ hybridization (FISH) assays are routinely used to select patients to receive trastuzumab, both assays only partially predict response to the drug. In the case of epidermal growth factor receptor (EGFR), the link between the presence of the receptor or its amplification and response to anti-EGFR therapies could not be demonstrated. Even less is known for HER3 and HER4, mainly due to lack of robust and validated assays detecting these proteins. It is becoming evident that, besides FISH and IHC, we need better assays to quantify HER receptors and categorize the patients for individualized treatments. Here, we present the current available methodologies to measure HER family receptors and discuss the clinical implications of target quantification.

Original language	English
Article number	53
Journal	Breast Cancer Research
Volume	17
Issue number	1
DOIs	https://doi.org/10.1186/s13058-015-0561-8
Publication status	Published - 9 Apr 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s13058-015-0561-8Licence: CC BY

s13058_015_0561_8Final published version, 471 KBLicence: CC BY

Cite this

@article{5a0a265a32314d2ebfe6396bec8aba0b,

title = "Quantification of HER family receptors in breast cancer",

abstract = "The clinical success of trastuzumab in breast cancer taught us that appropriate tumor evaluation is mandatory for the correct identification of patients eligible for targeted therapies. Although HER2 protein expression by immunohistochemistry (IHC) and gene amplification by fluorescence in situ hybridization (FISH) assays are routinely used to select patients to receive trastuzumab, both assays only partially predict response to the drug. In the case of epidermal growth factor receptor (EGFR), the link between the presence of the receptor or its amplification and response to anti-EGFR therapies could not be demonstrated. Even less is known for HER3 and HER4, mainly due to lack of robust and validated assays detecting these proteins. It is becoming evident that, besides FISH and IHC, we need better assays to quantify HER receptors and categorize the patients for individualized treatments. Here, we present the current available methodologies to measure HER family receptors and discuss the clinical implications of target quantification.",

author = "Paolo Nuciforo and Nina Radosevic-Robin and Tony Ng and Maurizio Scaltriti",

year = "2015",

month = apr,

day = "9",

doi = "10.1186/s13058-015-0561-8",

language = "English",

volume = "17",

journal = "Breast Cancer Research",

issn = "1465-5411",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Quantification of HER family receptors in breast cancer

AU - Nuciforo, Paolo

AU - Radosevic-Robin, Nina

AU - Ng, Tony

AU - Scaltriti, Maurizio

PY - 2015/4/9

Y1 - 2015/4/9

N2 - The clinical success of trastuzumab in breast cancer taught us that appropriate tumor evaluation is mandatory for the correct identification of patients eligible for targeted therapies. Although HER2 protein expression by immunohistochemistry (IHC) and gene amplification by fluorescence in situ hybridization (FISH) assays are routinely used to select patients to receive trastuzumab, both assays only partially predict response to the drug. In the case of epidermal growth factor receptor (EGFR), the link between the presence of the receptor or its amplification and response to anti-EGFR therapies could not be demonstrated. Even less is known for HER3 and HER4, mainly due to lack of robust and validated assays detecting these proteins. It is becoming evident that, besides FISH and IHC, we need better assays to quantify HER receptors and categorize the patients for individualized treatments. Here, we present the current available methodologies to measure HER family receptors and discuss the clinical implications of target quantification.

AB - The clinical success of trastuzumab in breast cancer taught us that appropriate tumor evaluation is mandatory for the correct identification of patients eligible for targeted therapies. Although HER2 protein expression by immunohistochemistry (IHC) and gene amplification by fluorescence in situ hybridization (FISH) assays are routinely used to select patients to receive trastuzumab, both assays only partially predict response to the drug. In the case of epidermal growth factor receptor (EGFR), the link between the presence of the receptor or its amplification and response to anti-EGFR therapies could not be demonstrated. Even less is known for HER3 and HER4, mainly due to lack of robust and validated assays detecting these proteins. It is becoming evident that, besides FISH and IHC, we need better assays to quantify HER receptors and categorize the patients for individualized treatments. Here, we present the current available methodologies to measure HER family receptors and discuss the clinical implications of target quantification.

UR - http://www.scopus.com/inward/record.url?scp=84926609225&partnerID=8YFLogxK

U2 - 10.1186/s13058-015-0561-8

DO - 10.1186/s13058-015-0561-8

M3 - Article

AN - SCOPUS:84926609225

SN - 1465-5411

VL - 17

JO - Breast Cancer Research

JF - Breast Cancer Research

IS - 1

M1 - 53

ER -

Quantification of HER family receptors in breast cancer

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this